Open AccessA new strategy for the treatment of sorafenib-refractory metastatic renal cell carcinoma in China: combination with intermittent chemotherapy
Author(s) -
Zicheng Xu,
Xiao Li,
Feng Qi,
Xin Hu,
Yuxiao Zheng,
Hongzhou Cai,
Ting Xu,
Bin Yu,
Qing Zou
Publication year - 2019
Publication title -
translational andrology and urology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.721
H-Index - 27
eISSN - 2223-4691
pISSN - 2223-4683
DOI - 10.21037/tau.2019.06.25
Subject(s) - medicine , sorafenib , gemcitabine , refractory (planetary science) , renal cell carcinoma , chemotherapy , progressive disease , gastroenterology , oncology , surgery , urology , hepatocellular carcinoma , physics , astrobiology
This study assesses the clinical safety and efficacy of Gemcitabine and S-1 combination chemotherapy in sorafenib-refractory metastatic renal cell carcinoma (RCC) patients.